Prometic Life Sciences - Durststrecke ade!
Seite 1 von 3 Neuester Beitrag: 05.04.23 13:58 | ||||
| Eröffnet am: | 16.02.11 10:49 | von: Oki-Wan 2.0 | Anzahl Beiträge: | 69 |
| Neuester Beitrag: | 05.04.23 13:58 | von: Vassago | Leser gesamt: | 28.026 |
| Forum: | Hot-Stocks | Leser heute: | 2 | |
| Bewertet mit: |  | |||
| Seite: < | 2 | 3 > | ||||
nachdem Prometic eine harte Durststrecke hinter sich gelassen hat und der Kurs dies auch widerspiegelt, mehren sich die Anzeichen dafür, dass 2011 und 2012 die bisher besten Jahre in der Unternehmensgeschichte werden könnten. Deswegen dieser neue Thread, da der alte namentlich etwas irreführend erscheint: Prometic ist mit Genta nicht zu vergleichen!
Zahlreiche Partnerschaften mit namhaften Pharmagrößen und Vertriebsspezialisten, Unterstützung verschiedener Regierungen und des Roten Kreuzes sowie eine zuletzt beschlossene Zusammenarbeit mit Allist Pharmaceuticals aus China machen dieses Unternehmen top interessant.
Sollten sich die Prognosen bewahrheiten und Prometic Ende dieses Jahres Lizenzzahlungen seines italienischen Partners Kedrion erhalten, dann sind alle Weichen auf Break-even gestellt.
Des Weiteren wartet man auf eine Entscheidung der britischen Regierung, ob der Einsatz von P-Capt-Filtern bei Blutentnahmen/-Spenden/-transfusionen gesetzlich vorgeschrieben werden soll - von einem Feuerwerk zu sprechen wäre dann schlicht untertrieben.
Und zum Schluss noch hier die letzte Pressemitteilung zum Bau einer neuen Fertigungsanlage, veröffentlicht am 08.02.2011 auf der Homepage:
http://www.prometic.com/docs/events/...ic_Laval_Facility_EN_FINAL.pdf
Lasst uns hier fundierte Prognosen veröffentlichen und daraus realistische Kursziele ableiten...
Beste Grüße,
Oki-Wan 2.0
Ich werde mich in der nächsten Zeit voll auf dieses Thema konzentrieren.
Falls also jemand Fragen, Anmerkungen oder Korrekturen bezüglich diesem Thema hat, soll er/sie dies frei und ungezwungen kund tun. Ich freue mich auf jedes partizipieren.
Beste Grüße,
Oki-Wan 2.0
Posted on February 20, 2011
ProMetic would like to bring to your attention a recently published article by Dr. R. Knight of the UK National CJD Surveillance Unit.
The article is titled "The risk of transmitting prion disease by blood or plasma products".
Points to note include the following sections 5. What can be done? that touches on four broad possible protective actions: donor selection, donation testing, infectivity inactivation and infectivity removal, and 6. Summary which is listed below.
6. Summary
Blood from vCJD donors contains infectivity that can be transmitted to recipients via red cell transfusion and, probably, via other products, including plasma and plasma derivatives. Many precautionary measures have been introduced but the magnitude of risk remains uncertain due to several unknowns, not least the uncertainty of the number of infected individuals in the general population.
There are no currently validated blood tests for prion infectivity. Blood prion filters have been developed and their adoption into clinical transfusion practice is being considered.
The P-Capt® prion filter, co-developed by ProMetic and MacoPharma SA, has been commercially available since 2006, and is the only proven approach to reducing the risk of vCJD transmission from red blood cell concentrate.
© Elsevier LTd. doi: 10.1016/j.transci.2010.09.003 Transfusion and Apheresis Science Journal 43 (2010) 387-391
Quelle:
http://www.prometic.com/en/prometic/information.php
Die Brisanz dieser News liegt in der Aussage des Dr. Knight, dass es momentan keine nachweislich geprüften Bluttests für Prioneninfektionen gibt:
"There are no currently validated blood tests for prion infectivity. "
Und das hier ist ein Faktenhammer:
Der P-Capt-Filter,..., ist seit 2006 verfügbar und der einzige nachweislich geprüfte Methode zur Risikominderung von vCJD-Übertragungen durch rote Blutkörper:
"The P-Capt® prion filter, co-developed by ProMetic and MacoPharma SA, has been commercially available since 2006, and is the only proven approach to reducing the risk of vCJD transmission from red blood cell concentrate."
Also kommt die Frage auf:
Worauf warten die Verantwortlichen noch? Auf Selbstheilung?
Der Einsatz der Filter ist schon längst überfällig!
Beste Grüße,
Oki-Wan 2.0
Das sind Prometics Partner (nur Sumitomo kann ich nicht entdecken, sind aber m.W. noch dabei):
About ProMetic
Partners
ProMetic is a world leader in Protein Technologies and in the development of therapeutics. The cross-section below is representative of some of the collaborations and agreements between ProMetic and its partners and / or clients. These are at various phases of development worldwide. Each one contributes to building a strong and diversified portfolio of business opportunities as well as providing ProMetic with long-standing relationships.
Bitte schaut euch doch mal alle den Kurs in Toronto an: 0,225 CAD !!!
Heute kam diese News raus:
Press Releases
ProMetic on target for its plasma-derived therapeutics business
- Second tranche of funds received; brings total investment in NewCo to date at $1.5 M
- ProMetic's headquarters on schedule to move to NewCo's facility by end of March
- NewCo's manufacturing facility on target to commence operations by end of 2011
MONTREAL, QUEBEC, CANADA - February 28, 2011 - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announced today that the Company received a second $750,000 investment tranche for its new subsidiary NewCo. This brings the total equity investment received to date to $1,500,000, as part of a $2,500,000 commitment.
On February 7, 2011, ProMetic announced that it had created NewCo to enter into a long-term lease on very favorable conditions for an existing state-of-the-art facility and to undertake the development and manufacturing of high-value plasma-derived therapeutic biosimilars for ProMetic's current and future clients. This facility, located in Laval, Quebec's biotech cluster, will have a targeted processing capacity of 150,000 L, allowing the supply of products with a market value exceeding $100,000,000 per annum.
The Company also disclosed that NewCo would be funded via third-party investments; with ProMetic's existing clients it is anticipated that NewCo will rapidly become self-sustaining through end product services and sales.
"This enabling project for ProMetic is attracting significant interest from strategic players and investors," stated Pierre Laurin, ProMetic's President and Chief Executive Officer.
NewCo will allow the Company to benefit, at commercial scale, from the competitive advantage provided by its proven Plasma Protein Purification System ("PPPSTM") as well as its prion capture technologies. The manufacturing plant will supply plasma-derived therapeutic products to ProMetic's existing and future clients, as well as allowing ProMetic to provide technology transfer and skills training services. The plant is expected to start up operations by the end of 2011, provide cGMP products to be used by clients in early 2012, and reach full operating capacity by 2014.
"The preparatory work for the relocation of ProMetic's headquarters to NewCo's facility has already started and the move should be completed by the end of March," commented Bruce Pritchard, ProMetic's Chief Financial Officer.
About the Plasma Protein Purification System
The Plasma Protein Purification System ("PPPSTM") allows for the targeting and removal of multiple high-value proteins from a single plasma sample at unprecedented activity levels using ProMetic's Mimetic LigandTM adsorbent technology. This system also provides for the recovery of new biotherapeutics as they are discovered and identified. The effect of this process is to reduce the significant losses incurred when using the more conventional Cohn precipitation process
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (http://www.prometic.com/) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic LigandTM technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montréal (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and business development activities in the U.S., Europe, Asia and in the Middle-East.
Forward Looking Statements
This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 24 of ProMetic's Annual Information Form for the year ended December 31, 2009, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless stated otherwise.
oki, danke für dein gespür. du hast mich auf die aktie gebracht ;-)
Das Volumen der letzten Tage war jedenfalls eine Augenweide und spricht für die gesteigerte Aufmerksamkeit für unsere PLI bei den Anlegern.
Allen weiterhin viel Glück und Beste Grüße,
Oki-Wan 2.0
Hier nochmal die Vorstellung von PBI-1402, neben P-Capt und der Purification-Technologie der Hoffnungsträger bei PLI:
Anemia – PBI 1402
ProMetic’s lead candidate drug, PBI-1402, addresses substantial unmet medical needs.
- PBI-1402 is orally active, whereas most other drugs treating anemia are injectables.
- PBI-1402 has shown anticancer activity in multiple pre-clinical models.
- PBI-1402, all the while mimicking EPO’s biological activity, has a distinct mechanism of action from EPO, as it does not bind to the same cell surface receptor as EPO. It therefore provides great promise of serving as a stand-alone therapeutic in the treatment of patients with anemia.
- PBI-1402 is an affordable low molecular weight synthetic candidate drug, relative to costly recombinant proteins, such as EPO.
- PBI-1402 addresses a worldwide marketplace that exceeds $15 billion.
PBI-1402 for the treatment of Anemia indications
The initial indication targeted by PBI-1402 is anemia in cancer patients undergoing chemotherapy. Upwards of two thirds of cancer patients treated with chemotherapy develop anemia. Treatment with EPO, the current drug of choice for this indication, is active in only 50 to 60 percent of these patients.
PBI-1402 has reported positive clinical results in the chemotherapy-induced anemia trial and demonstrated excellent safety and tolerability, as well as an impressive efficacy profile. A Phase II trial of PBI-1402 demonstrated a significant increase in the red blood cell count and the hemoglobin level in patients with chemotherapy-induced anemia (“CIA”). In this open-label Phase II trial, patients each received PBI-1402 once daily at doses ranging from 44mg/kg to 88mg/kg. Analysis of the data showed that only 2 patients out of 28 (7%) treated with PBI-1402 required a RBC transfusion, a response rate greater than 90% with regards to this clinical objective. In the March 13, 2008 FDA briefing document, the Oncology Drugs Advisory Committee emphasizes that the primary objective of treating CIA patients with erythropoiesis-stimulating agents (“ESAs”) as being the ability to reduce the need for RBC transfusion. The Advisory Committee cites that approximately 50% of anemic patients receiving chemotherapy required RBC transfusion, and 20%-25% of patients treated with ESAs still required RBC transfusions.
The encouraging positive results from the CIA clinical trial and the anticancer effects reported in animal models seem to indicate that PBI-1402 is well suited for the treatment of anemia in oncology, resulting in the PBI-1402 clinical platform being extended to patients suffering from cancer-related anemia. Moreover, approximately twenty million patients in the U.S. alone are diagnosed with chronic kidney diseases (“CKD”). Patients diagnosed at severe CKD stages (3 and 4) often develop anemia before they require hemodialysis. CKD patients still at the pre-dialysis stage could greatly benefit from an orally administered drug as a treatment for their anemia.
Recent experiments based on a 5/6 nephrectomized rat model have demonstrated the ability of PBI-1402 to correct anemia. This model simulates chronic renal failure in humans, a condition whereby the kidneys fail to produce sufficient EPO for the stimulation of red blood cell production. These results indicate additional potential for PBI-1402.
Ich denke, es wird Zeit für PLI auch hier den Schleier zu lüften. Die letzte Meldung zu PBI-1402 wurde in Zusammenhang mit der Kooperationsvereinbarung mit Allist Pharmac. veröffentlicht. Mir wurde mal gesagt, PLI sei ein "One-Trick-Pony" und ich habe damals dem zugestimmt. Jedoch revidiere ich jetzt diese Aussage. Prometic hat mehrere heisse Produkte bzw. Produktkandidaten und längst nicht mehr von dem Erfolg eines Produktes abhängig.
Hier der Link:
http://www.prometic.com/en/therapeutics/anemia-PBI-1402.php
Beste Grüße,
Oki-Wan 2.0
Beste Grüße,
Oki-Wan 2.0
ProMetic Corporate Update
MONTREAL, QUEBEC, CANADA - March 8, 2011 - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") today announced, that on the back of its growing operations, the Company has elected to split the roles of Chairman and Chief Executive Officer. Mr. G.F. Kym Anthony has agreed to accept the position of Chairman of the Board of Directors in order to better support ProMetic's Chief Executive Officer with the execution of key value drivers during 2011. Mr. Anthony has been a longtime serving member of ProMetic's Board of Directors.
"This is a pivotal year for ProMetic. The level of moving parts involved in the execution of ProMetic's strategic plan for our different business units requires the undivided attention of Mr. Pierre Laurin, our President and Chief Executive Officer. The recently created NewCo subsidiary for the manufacturing of plasma-derived therapeutics is just one example of what is expected to create shareholder value this year," stated Mr. Anthony who went on to add: "ProMetic's Board of Directors fully supports Mr. Laurin's vision for the Company. As Chairman, I will devote more time to support the Chief Executive Officer and to manage the Board and governance functions of the business".
Mr. Laurin commented: "I am delighted that Kym has decided, amongst his various options, to make ProMetic's future growth his priority. The Company will benefit, through Kym's increased involvement, from the additional wealth of experience that he brings to the position of Chairman and to the building of value for corporations. In addition, ProMetic is demonstrating best corporate governance practices by separating the role of Chairman of the Board from that of Chief Executive Officer".
Over the last two years, the Company has appointed a Board member to act as Lead Director in support of the Chief Executive Officer and as liaison with the Board and Mr. Benjamin Wygodny served in this capacity. With the Company's continued growth, the separation of the roles of Chairman and Chief Executive Officer is now formalized through Mr. Anthony's nomination as Chairman, in effect replacing the position of Lead Director. Mr. Wygodny will continue in his mandate as a Director on ProMetic's Board.
About Mr. G.F. Kym Anthony
Mr. G.F. Kym Anthony is an experienced and successful capital markets executive with over 30 years in the financial services and investment banking industries. He rose through the senior executive ranks of CIBC and its investment bank unit, Wood Gundy. He later became the Chair and Chief Executive Officer of TD Securities and a Vice-Chair of TD Bank, where he led the creation and development of TD Securities. Mr. Anthony was also the President and Chief Executive Officer of National Bank Financial, the investment banking and capital markets unit of National Bank of Canada for six years and CEO of Dundee Securities. Mr. Anthony has held a number of senior positions in the financial services industry, including being Chair of the Investment Dealers Association of Canada, and serves on several corporate and nonprofit boards. Mr. Anthony is also currently Chairman of Broadacre Agriculture and DFG Investment Advisors and a board member of ComDev International.
http://www.prometic.com/en/news-events/...ic-corporate-update-637.php
"This is a pivotal year for ProMetic. The level of moving parts involved in the execution of ProMetic's strategic plan for our different business units requires the undivided attention of Mr. Pierre Laurin, our President and Chief Executive Officer. The recently created NewCo subsidiary for the manufacturing of plasma-derived therapeutics is just one example of what is expected to create shareholder value this year," stated Mr. Anthony who went on to add: "ProMetic's Board of Directors fully supports Mr. Laurin's vision for the Company. As Chairman, I will devote more time to support the Chief Executive Officer and to manage the Board and governance functions of the business".
Entschuldigt mich bitte, aber diese Äußeruung geht bei mir runter wie Butter.
Und "Pivotal Year for Prometic" kann ich nur unterstreichen; bei denen wird sich dieses Jahr, wie ich schon vorher geschrieben habe, ziemlich vieles ändern. Hoffen wir weiterhin, dass es die Shares explodieren lässt. Ich warte nun auf die Entscheidungen des britischen Unterhauses zur P-Capt-Einführung und den ersten Lizenzzahlungen von Kedrion.
Beste Grüße,
Oki-Wan 2.0
|
ich kann es nicht oft genug sagen/schreiben, aber der Kurs wird in Übersee gemacht, siehe hier:
http://tmx.quotemedia.com/quote.php?qm_symbol=PLI&locale=en
Auf die Kurse in Frankfurt und Co. gebe ich nicht einmal einen feuchten ..., ihr wisst schon was. Umgerechnet liegen wir bei knapp über 15 Eurocent!!! bzw. 0,205 CAD.
Weiter geht's mit PLI und wie immer alles Gute den hier Investierten.
Beste Grüsse,
Oki-Wan 2.0
wann wird genau die knete von kedrion erwartet?
Freut mich auf jeden Fall. Ich dachte nämlich, dass du mit Gewinn ausgestiegen bist.
Ok. Aber jetzt kein OFFTOPIC mehr.
Die Sachen zu Kedrion werde ich hier reinstellen, sobald ich sie gefunden habe (suche das ursprüngliche Agreement).
Bis dahin beste Grüße an alle,
Oki-Wan 2.0
Hier ist wie versprochen die Pressemitteilung zu Kedrion vom 25.02.2008. Es fehlt aber noch der Teil, welcher die besagten Revenues für Prometic ab 2011 erwartet. Diese liefere ich noch nach. Soweit ich mich erinnere waren diese auf einem Quartals-/Jahresbericht aufgelistet.
Beste Grüße, Oki-Wan 2.0
( http://www.prometic.com/en/news-events/...tive-license-452.php?y=2008 )
ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
- Kedrion has in-licensed ProMetic's yield improving technology
- $30 M potential annual revenue derived from ProMetic sales of the first hyperimmune product in the U.S. market
- Incorporation of ProMetic's technology in Kedrion's manufacturing process
MONTREAL, QUEBEC (CANADA) - February 26, 2008 - ProMetic Life Sciences Inc. ("ProMetic") (TSX:PLI) announced today that it has signed the definitive agreement for development of two hyperimmunes with Kedrion S.p.A. ("Kedrion").
Terms of this agreement call for upfront and milestone payments, as well as service fees to ProMetic. Potential revenues to ProMetic from Hepatitis B Hyperimmune direct sales in North America are to exceed $30 M annually, which are expected to commence in 2011.
The first product to be developed will target the Hepatitis B Hyperimmune market which is currently estimated in Europe and in the U.S. to be at $200 M and is expected to be at $400 M by 2015.
Kedrion has in-licensed ProMetic's technologies for the manufacturing of hyperimmune products in Europe. Royalties, licensing and service fees for the sales of products in Europe will be paid by Kedrion to ProMetic with ProMetic retaining the commercial rights for the fully developed hyperimmune products for the North American market. ProMetic will in turn pay Kedrion royalties on its sales of the hyperimmune products in North America.
The product development program, including the clinical trial designed to meet U.S. and European regulatory requirements will be funded by Kedrion, who will be the holder of the products registration for both markets.
"This agreement with Kedrion will leverage ProMetic's ability to penetrate into the North American hyperimmune product market and expand on our existing revenue base," commented Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic.
More about Hepatitis B
HB, hepatitis B IVIG is primarily used in preventing reinfection with hepatitis B in HBV positive liver transplant patients. It is also used in the treatment of acute exposure to hepatitis B following acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg positive persons, and household exposure of infants to persons with acute hepatitis B virus infection. The groups usually considered at risk are hepatitis B researchers and workers, and many health care professionals.
More about Kedrion S.p.A.
Kedrion (http://www.kedrion.com/) is a biopharmaceutical company specialized in the development, production, commercialization and distribution of plasma-derived products. Born in 2001 following the rationalisation and upgrading of other companies working in this field, it acquired a heritage of expertise that secures it a prominent role in Italy, in Europe and in the world. Kedrion is present in over 40 countries. It's head office is in Tuscany, Castelvecchio Pascoli, near Lucca.
In Italy, Kedrion is a partner of the National Health Service for the production of plasma-derived medicinal products. In addition, its expertise serves other strategic partnerships with health institutions in other countries.
Kedrion's activities are carried on through different companies and three authorized production plants: Bolognana, near Lucca (Tuscany); S. Antimo, near Naples; Gödöllő, near Budapest. Kedrion works in four business areas: production and commercialization of plasma-derived products obtained from the plasma fractionation process; commercialization of flu vaccines and synthetic pharmaceutical products; plasma collection and commercialization in foreign markets; other activities, among them in particular transfer of technological know-how. The three principal types of plasma-derived products produced by Kedrion are: standard and hyperimmune immunoglobulin, albumin and coagulation factors (procoagulants and anticoagulants).
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (http://www.prometic.com/) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montréal (Canada), ProMetic has R&D facilities in the UK, the USA and Canada, manufacturing facilities in the UK and business development activities in the USA, Europe, Asia and in the Middle-East.
"Potential revenues to ProMetic from Hepatitis B Hyperimmune direct sales in North America are to exceed $30 M annually, which are expected to commence in 2011.
The first product to be developed will target the Hepatitis B Hyperimmune market which is currently estimated in Europe and in the U.S. to be at $200 M and is expected to be at $400 M by 2015."
Also nochmal: ab 2011 werden Revenues durch den Verkauf in Nordamerika erwartet; das Potential wird auf 200 Mio. $ geschätzt, 2015 auf 400 Mio $ (Europa und USA).
Es wird also in erster Linie auf Einnahmen aus dem Nordamerika-Geschäft hingewiesen. Kedrion hat mit Prometic eine Abmachung getroffen, um die Hyperimmune-Produkte in Europa vertreiben zu können. Dafür werden sie Prometic Lizenzgebühren etc. zahlen. Prometic wiederum zahlt an Kedrion eine bestimmte Gebühr, abhängig von der Höhe der Einnahmen in Nordamerika.
Beste Grüße,
Oki-Wan 2.0
Heute per Mail erhalten. Viel Spaß beim lesen und beste Grüße,
Oki-Wan 2.0
|
Since 1987 ist hier eine Übersicht zu den Messen, auf denen Prometic Bio vertreten sein wird.
Einen schönen Abend wünsche ich allen,
Oki-Wan 2.0
PBL are proud to support the following key industry event(s). Come meet us at the following conferences:
Mit besten Grüßen,
Oki-Wan 2.0
| New Event Announcement BioProcess International Europe Conference and Exhibition Since 1987 ProMetic BioSciences Ltd (PBL) has been pioneering design, development and manufacture of affinity purification technology for large scale commercial bioprocessing as well as research and development at lab-scale in the biotechnology industry.  Come see us at the BioProcess International Europe Conference and Exhibition taking place April 6-7th at the Nice Acropolis Des Congres, Nice France. Europe's largest bioprocessing conference, the BioProcess International Europe Conference and Exhibition brings together innovation, science and solutions to drive every stage of biomanufacturing.Stop by our booth to learn more about PBL's creative affinity chromatography adsorbents.
Conference: April 6-7 Book a Meeting To make an appointment to meet with representatives of PBL at the BioProcess International Europe Conference and Exhibition, click here. |
  |
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - |
habe was im netz gefunden aber nicht schlauer geworden
es ist von einer nicht eingehaltenen frist die rede (annual report 2010)